title: [Diet and drugs in the therapy of nonorganic dyspepsia: the hypothesis and factual data].
abstract: Non-organic dyspepsia, although not frequently reported, is still a disorder which is difficult to classify in nosographic and physiopathological terms, a fact which inevitably influences the indications for its treatment. Non-pharmacological treatment of non-organic dyspepsia includes changes in dietary and behavioural habits which, even if established on empirical grounds, play a far from ancillary role. When considered appropriate, pharmacological treatment must be formulated solely on the basis of controlled clinical trials vs placebo given the well-known significance of the placebo effect in this and other so-called "functional" diseases. The therapeutic strategies which are most subject to verification are based on the one hand on the neutralisation or inhibition of gastric acid secretion and, on the other, on the improvement of gastrointestinal motility. Surprisingly, the widely used antacid drugs are among those which have been less well studied and show the lowest efficacy. Among the anti-secretory drugs, pirenzepine is approximately 25% more effective than placebo. H2-antagonists, the drugs which have been most closely studied both in terms of the number of trials and the size of the sample populations studied, produce contradictory results. However, a meta-analysis of the trials shows an overall 18% improvement in efficacy compared to placebo. The overall results of studies on prokinetic compounds are "good" in meta-analytical terms, with an improved efficacy of 50% compared to placebo. This is not necessarily due to the superiority of prokinetic compared to anti-secretory drugs and can be explained by the reduced placebo effect in trials using prokinetic drugs or a greater presence in the latter of dyspepsia which is physiopathologically correlated to motor discord. Among the future drugs still being studied, it is particularly worth mentioning fedotozine, a specific K opioid receptor agonist which appears to have provided extremely interesting results in preliminary studies. The role of barrier drugs, such as sucralfate and colloidal bismuth, continues to remain unclear and in particular the latter might be of increased use if evidence of a relationship between Helicobacter pylori and non-organic dyspepsia were reinforced; this relationship may in fact not exist in all dyspeptic patients but only in a subgroup. Lastly, the problem of the duration of pharmacological treatment still remains unsolved, as do the questions of whether longterm treatment should be conceived once acute symptoms have disappeared and whether it is possible to hypothesise differentiated pharmacological treatment depending on the clinical variants of functional dyspepsia which have been defined with greater attention over the course of the past decade.
authors.affiliation: Divisione di Gastroenterologia, Ospedale Generale Regionale, Bolzano.
authors.forename: G
authors.initials: G
authors.lastname: Dobrilla
authors.forename: I
authors.initials: I
authors.lastname: Zancanella
authors.forename: S
authors.initials: S
authors.lastname: Benvenuti
authors.forename: M
authors.initials: M
authors.lastname: Comberlato
authors.forename: S
authors.initials: S
authors.lastname: Amplatz
authors.forename: F
authors.initials: F
authors.lastname: Di Fede
authors.forename: A
authors.initials: A
authors.lastname: De Guelmi
mesh_terms: D003131:Combined Modality Therapy; D004415:Dyspepsia / Q000178:diet therapy* / Q000188:drug therapy* / Q000503:physiopathology; D016481:Helicobacter Infections / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology; D016480:Helicobacter pylori; D006801:Humans
vernacular_title: Dieta e farmaci nella terapia della dispepsia non organica: ipotesi e dati di fatto.